PHAXIAM Therapeutics S.A.
PHXM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $20 | $10 | $49 | $151 |
| - Cash | $10 | $39 | $34 | $44 |
| + Debt | $11 | $14 | $25 | $27 |
| Enterprise Value | $21 | -$16 | $41 | $134 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$2 | -$3 | -$5 | -$5 |
| % Margin | – | – | – | – |
| EBITDA | -$23 | -$3 | -$48 | -$66 |
| % Margin | – | – | – | – |
| Net Income | -$23 | -$0 | -$54 | -$73 |
| % Margin | – | – | – | – |
| EPS Diluted | -4.62 | -0.1 | -22.7 | -36.55 |
| % Growth | -4,520% | 99.6% | 37.9% | – |
| Operating Cash Flow | -$24 | -$32 | -$57 | -$52 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$25 | -$32 | -$57 | -$53 |